Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders)

Editorial [Tuberculosis Drugs and Drug Targets]
pp. 71-72(2)
Authors: Robert C. Goldman; Barbara E. Laughon

The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control
pp. 73-91(19)
Authors: Robert C. Goldman; Kevin V. Plumley; Barbara E. Laughon

Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility
pp. 92-104(13)
Authors: R. C. Goldman; B.E. Laughon; R. C. Reynolds; J. A. Secrist; J. A. Maddry; M.-A. Guie; A. C.Poffenberger; C. A. Kwong; S. Ananthan

Challenges Associated with Current and Future TB Treatment
pp. 105-119(15)
Authors: M. Laurenzi; A. Ginsberg; M. Spigelman

Molecular Approaches to Target Discovery: - Evaluating Targets for Antituberculosis Drug Discovery Programmes
pp. 120-126(7)
Authors: T. S. Balganesh; B. J. A. Furr

High Throughput Crystallography of TB Drug Targets
pp. 127-139(13)
Authors: A.C. Murillo; H.Y. Li; T. Alber; E.N. Baker; J.M. Berger; L.T. Cherney; M.M. Cherney; Yoon Song Cho; D. Eisenberg; C.R. Garen; C.W. Goulding; L. W. Hung; T.R. Ioerger; W.R. Jacobs; M.N.G.James; C. Kim; I. Krieger; J.S. Lott; R. Sankaranarayanan; B.W. Segelke; T.C. Terwilliger; F.Wang; S. Wang; J.C. Sacchettini

Drug Targets in Mycobacterial Sulfur Metabolism
pp. 140-158(19)
Authors: Devayani P. Bhave; Wilson B. Muse III; Kate S. Carroll

Mycobacterium tuberculosis DNA Gyrase as a Target for Drug Discovery
pp. 159-168(10)
Authors: Khisimuzi Mdluli; Zhenkun Ma

Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
pp. 169-181(13)
Authors: J. S. Teh; T. Yano; H. Rubin

Targeting the Formation of the Cell Wall Core of M. tuberculosis
pp. 182-202(21)
Authors: Clifton E. Barry; Dean C. Crick; Michael R. McNeil